Natco Pharma share news, announcements and annual reports
NSE: NATCOPHARMBSE: 524816Pharmaceuticals & BiotechnologySmall Cap
Natco Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Dec 1995 on NSE
Last close ₹785.75up ₹3.35 (0.43%)BSE ₹786.05
Share price at the NSE close on 2 Nov 2026. Previous close ₹782.40.
2 Nov: open ₹790.05, high ₹791.75, low ₹780.95
52-week range of traded prices to 2 Nov 2026
₹773.60Low, 22 Oct 2026₹1,226.80High, 12 May 2026
- Next results date: the board meets on 13 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,414 Cr380th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.47
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.57%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.08
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,00,99056.3% delivered
Natco Pharma share news and announcements
1,035 announcements, routine notices left out, newest first. Page 15 of 21.
Apr 2014
Mar 2014
Feb 2014
13 Feb · Results
13 Feb · Corporate action
Company has fixed Record Date as February 25, 2014 for the purpose of Interim dividend13 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 13, 2014 has considered and approved the following: (1) Mr. Vivek Chhacchi, Nominee Director of CX Securities Ltd. and Mr. D. G. Prasad, Independent Director inducted as Additional Directors. Mr. Nitin Jagannath Deshmukh resigned as a Director due to his personal preoccupation.13 Feb · Dividend
Interim dividend pay by date is March 06, 2014.13 Feb · Dividend
Board of Directors of the Company at their meeting held on February 13, 2014 the Board has recommended payment of an interim dividend of Rs. 5/- per equity share of Rs. 10/- each for the year 2013-2014.3 Feb · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended December 31, 2013, to consider Interim Dividend, if any, for the financial year 2013-14 and related matters etc.
Dec 2013
Nov 2013
29 Nov · Business
Duly constituted Committee of Directors, at a meeting held on November 29, 2013 allotted 17,00,000 equity shares of Rs. 10/- each at a premium of Rs. 628.40 per share on a Preferential basis to M/s. CX Securities Limited, Mauritius.14 Nov · Disclosure of Voting Pattern - Clause 35A
5 Nov · Board meeting
To consider among other things, the unaudited financial results for the quarter ending September 30, 2013 and related matters.
Oct 2013
21 Oct · Business
11 Oct · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in Natco Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Natco Pharma Limited has vide its letter inter-alia stated, "We do not have information as to the reasons thereof."
Sep 2013
Aug 2013
14 Aug · Board meeting
14 Aug · Meeting
The Register of Members and Share Transfer Books of the Company will remain closed from September 25, 2013 to September 28, 2013 (both days inclusive) for the purpose of Annual General Meeting of the Company to be held on September 28, 2013.2 Aug · Board meeting
To consider among other things, the unaudited financial Results for the quarter ended June 30, 2013, convening of Annual General Meeting and related matters etc.
Jul 2013
Jun 2013
20 Jun · Updates
Designation of Mr. M. Adinarayana, Compliance Officer has been redesignated as Company Secretary & Vice President (Legal & Corporate Affairs).4 Jun · Board meeting
To consider the audited consolidated financial statements.
May 2013
30 May · Management
Dr. Jasti Sambasiva Rao, Director of the Company resigned as a Director due to his personal preoccupations.20 May · Board meeting
To consider among other things, approval of the Audited Results for the quarter ending March, 2013 along with Audited Annual Accounts for the year 2012-2013 and related matters.
Mar 2013
Feb 2013
13 Feb · Corporate action
Company has fixed Record Date as February 25, 2013 for the purpose of payment of interim dividend.13 Feb · Dividend
Interim dividend declared at the Board Meeting pay-by-date is March 06, 2013.